Free Trial
NYSE:ELAN

Elanco Animal Health Q3 2025 Earnings Report

Elanco Animal Health logo
$19.77 -0.30 (-1.49%)
Closing price 03:59 PM Eastern
Extended Trading
$19.76 0.00 (-0.03%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health EPS Results

Actual EPS
N/A
Consensus EPS
$0.13
Beat/Miss
N/A
One Year Ago EPS
N/A

Elanco Animal Health Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.09 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elanco Animal Health Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 5, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Elanco Animal Health Earnings Headlines

Elanco Animal Health (NYSE:ELAN) Upgraded at JPMorgan Chase & Co.
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Elanco Animal Health (NYSE:ELAN) Hits New 52-Week High on Analyst Upgrade
Acadia Healthcare Names Todd Young Finance Chief
See More Elanco Animal Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elanco Animal Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elanco Animal Health and other key companies, straight to your email.

About Elanco Animal Health

Elanco Animal Health (NYSE:ELAN) Inc. is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018. Since then, Elanco has pursued strategic acquisitions to strengthen its global footprint and expand its R&D capabilities. A notable milestone was the 2020 acquisition of Bayer’s Animal Health business, which added complementary products and bolstered Elanco’s presence across Europe, Latin America, Asia-Pacific and North America.

Elanco operates a network of research centers, manufacturing sites and distribution facilities around the world, enabling it to serve customers in more than 90 countries. The company invests in collaborations with universities, industry partners and veterinarians to advance its pipeline of biologics and pharmaceuticals. Under the leadership of President and Chief Executive Officer Jeffrey Simmons, Elanco continues to focus on innovation, sustainability and responsible use of medicines to address emerging health challenges in animal agriculture and companion care.

View Elanco Animal Health Profile

More Earnings Resources from MarketBeat